Recombinant Adeno Associated Virus Mediated Cooverexpression of Transforming Growth Factor Beta and Sox9 Genes Enhance the Metabolic and Chondrogenic Activities in Human Bone Marrow Aspirates
K. Tao,A. Rey-Rico,J. Frisch,J. K. Venkatesan,G. Schmitt,H. Madry,J. Lin,M. Cucchiarini
DOI: https://doi.org/10.1016/j.joca.2017.02.733
IF: 7.507
2017-01-01
Osteoarthritis and Cartilage
Abstract:Purpose: Transplantation of genetically modified bone marrow concentrates is an attractive approach to conveniently activate the chondrogenic differentiation processes as a means to improve the intrinsic repair capacities of damaged articular cartilage [1]. Here, we examined the potential benefits of co-overexpressing the pleiotropic transformation growth factor beta (TGF-β) and the cartilage-specific transcription factor sox9 using recombinant adeno-associated virus (rAAV) vectors upon the chondroreparative processes in human bone marrow aspirates. Methods: rAAV were packaged, purified, and titrated as previously described [1,2]. rAAV-lacZ carries the E. coli β-galactosidase gene (lacZ) controlled by the CMV-IE promoter/enhancer. AAV-hTGF-β carries a 1.2-kb human TGF-β (hTGF-β) cDNA fragment and rAAV-FLAG-hsox9 a 1.7-kb FLAG-tagged human sox9 (hsox9) cDNA, both cloned in rAAV-lacZ in place of lacZ [1,2,3]. Human bone marrow aspirates (∼ 15 ml) were obtained from the distal femurs of patients undergoing total knee arthroplasty (n = 8) [1]. Aspirates were aliquoted in standard tissue culture plastic 96-well plates (100 μl of aspirate/well) and immediately transduced with the rAAV vectors (rAAV-lacZ: 20 or 40 μl) or co-transduced (rAAV-hTGF-β /rAAV-FLAG-hsox9: 10 or 20 μl each vector) with each aliquot (8 x 105 functional recombinant viral particles, MOI = 10 ± 3). A volume of 60 μl of chondrogenic medium was then added per aspirate [1,2,3,4]. To assess TGF-β secretion, 30 μl of culture supernatant were collected at the denoted time points 24 h after medium change and TGF-β production was measured by ELISA as previously described. Transgene expression (lacZ, TGF-β, sox9, FLAG), and expression of type-II, -I, and -X collagen were assessed by immunohistochemical analyses. Hematoxylin eosin (H&E) for cellularity, toluidine blue for matrix proteoglycans, and alizarin red for matrix mineralization were also measured [1,2,3,4]. Each condition was performed in duplicate in three independent experiments. The one way ANOVA was analysed with P ≤ 0.050 as statistically significant. Results: Successful TGF-β/sox9 combined gene transfer and overexpression via rAAV was achieved in fresh, chondrogenically induced human bone marrow aspirates for up to 21 days (Fig. 1), the longest time point evaluated, leading to increased proliferation, matrix synthesis, and chondrogenic differentiation relative to control treatments (reporter lacZ treatment, absence of vector application), especially when co-applying the candidate vectors at the highest vector doses tested (Fig. 2). Optimal co-administration of TGF-β with sox9 also advantageously reduced hypertrophic differentiation in the aspirates (Fig. 3). Conclusions: Our results first indicate that combined TGF-β /sox9 gene transfer (especially at the highest vector doses employed) allowed for the sustained expression of SOX9 as previously noted with single rAAV-FLAG-hsox9transduction and to a durable production of TGF-β relative to the control conditions, in the range of those achieved when providing rAAV-hTGF-β alone [1]. The present data further show that prolonged, effective co-overexpression of TGF-β and sox9 led to increased levels of cell proliferation, matrix biosynthesis, and chondrogenic differentiation in the aspirates over time (at least 21 days) [3]. Equally important, combined TGF-β /sox9transduction advantageously delayed premature hypertrophic differentiation in the aspirates versus control treatments, again in good agreement with the known anti-hypertrophic activities of SOX9 that may counterbalance possible hypertrophic effects of TGF-β. These findings report the possibility of directly modifying bone marrow aspirates by combined therapeutic gene transfer as a potent and convenient future approach to improve the repair of articular cartilage lesions. References: [1] Frisch et al., J Cell Mol Med 2016, 430; [2] Cucchiarini et al., Tissue Eng Part A 2011, 1921; [3] Tao et al., Stem Cell Res Ther 2016, 20; [4] Rey-Rico et al., Gene Ther 2015, 50. Acknowledgement: This research was funded by grants from the National Natural Science Foundation of China (NSFC, No. 81672183 and 81541134), the Research and Development funds of Peking University People's Hospital (No. RDB2015-10), the Osteoarthritis Research Society International (OARSI 2015 Scholarship Award), and the German Osteoarthritis Foundation (Deutsche Arthrose-Hilfe e.V.).